Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery
  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

News in Brief

SBRT Effective for Inoperable Early-Stage Lung Cancer

DOI: 10.1158/2159-8290.CD-NB2014-158 Published December 2014
  • Article
  • Info & Metrics
Loading

The prognosis for non–small cell lung cancer (NSCLC) is best for the 20% of patients whose disease is detected early: Surgery is standard, and 60% to 80% are cured. However, due to comorbidities such as emphysema and heart disease, some patients are ineligible for surgery and fare worse on the traditional alternative—conventional fractionated radiotherapy, with a 2-year survival rate below 40%.

Stereotactic body radiation therapy (SBRT) may be a better option for these patients, says Robert Timmerman, MD, vice chair of radiation oncology at The University of Texas Southwestern Medical Center in Dallas, and principal investigator of RTOG 0236, the first phase II multicenter trial examining SBRT in patients with NSCLC who cannot tolerate surgery. He recently presented updated results of this study—first published in 2010—at the 2014 annual meeting of the American Society for Radiation Oncology in San Francisco, CA.

Within 5 years of SBRT, Timmerman reported, only 7% of 55 evaluable patients had primary tumor recurrence (at the site of origin). Another 38% of patients experienced spread of their disease within the same lobe or to nearby lymph nodes. The 5-year overall survival rate was 40%.

“Potential cures for lung cancer must be judged at least partly on their ability to control primary disease,” Timmerman says. SBRT, he adds, delivers on this essential requirement, at a rate similar to surgery. With SBRT, a few large doses of radiation directed from multiple angles overlap atop the tumor, ensuring highly focused delivery and minimal damage to surrounding tissue. Treatment time, usually 1.5 to 2 weeks, is also shorter than the 6 weeks required for conventional radiotherapy.

“No other approach looks as promising,” agrees Walter Curran, MD, chair of radiation oncology and director of Emory University's Winship Cancer Institute in Atlanta, GA.

Figuring out how to apply SBRT to lung tumors close to the central airway is also critical, Curran notes. The patients on RTOG 0236 all had peripheral tumors, but patients with central lung tumors face a greater risk of life-threatening injuries and bleeding from aggressive radiotherapy. He is eagerly awaiting results from RTOG 0813, a trial exploring the best SBRT dose and treatment schedule for these tumors.

With the positive long-term data from RTOG 0236, most U.S. oncologists now consider SBRT the new standard for inoperable early-stage NSCLC, Timmerman says. Whether SBRT will prove surgery's equal for patients who are candidates for surgery remains to be seen; attempts to set up a randomized trial comparing both therapies have been unsuccessful thus far.

“It's psychologically difficult for patients to let a coin flip decide between such disparate therapies,” Timmerman explains. However, he thinks that the design of a planned phase III trial that will prerandomize patients to surgery or SBRT and then obtain their informed consent—a concept called Zelen's design—may overcome this barrier; more than 80% of patients accepted prerandomization in other studies.

Ultimately, “we do need at least one high-level comparison,” Timmerman says. “Otherwise, SBRT's penetration into the treatment arsenal will be much slower.”

  • ©2014 American Association for Cancer Research.
View Abstract
PreviousNext
Back to top
Cancer Discovery: 4 (12)
December 2014
Volume 4, Issue 12
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
SBRT Effective for Inoperable Early-Stage Lung Cancer
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
SBRT Effective for Inoperable Early-Stage Lung Cancer
Cancer Discov December 1 2014 (4) (12) OF2; DOI: 10.1158/2159-8290.CD-NB2014-158

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
SBRT Effective for Inoperable Early-Stage Lung Cancer
Cancer Discov December 1 2014 (4) (12) OF2; DOI: 10.1158/2159-8290.CD-NB2014-158
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Proteomics Sharpens Brain Tumor Genomic Analysis
  • Uncovering a Culprit in CAR-T Resistance
  • Artificial Intelligence Predicts Drug Response
Show more News in Brief
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement